Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials

Published on January 7, 2025

of 2025. Upsized financing round led by a syndicate of top institutional investors, including Jeito Capital, only European fund within the